
Browsing restrictions can be lifted for a fee.
All Cosmos Bio-Tech Holding Corporation, through its subsidiaries, manufactures and sells bio-organic and bio-chemical compound fertilizers in Malaysia. It also engages in the research and development of microorganisms for waste disposal of oil-palm; and wholesale of probiotics. In addition, the company is involved in the research and forest plantation activities. It also exports its products to Taiwan, Indonesia, Vietnam, and China. All Cosmos Bio-Tech Holding Corporation was founded in 1999 and is headquartered in George Town, the Cayman Islands.
4148
全宇生技-KY
-0.96%
(-0.01)
The most recent financial report for 全宇生技-KY (4148) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4148's short-term business performance and financial health. For the latest updates on 4148's earnings releases, visit this page regularly.
According to historical valuation range analysis, 全宇生技-KY (4148)'s current price-to-earnings (P/E) ratio is 10.18, placing it in the Value zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
According to the latest financial report, 全宇生技-KY (4148) reported an Operating Profit of 95.86M with an Operating Margin of 11.55% this period, representing a growth of 15.11% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, 全宇生技-KY (4148) announced revenue of 829.8M, with a Year-Over-Year growth rate of 11.19%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, 全宇生技-KY (4148) held Total Cash and Cash Equivalents of 723.3M, accounting for 0.19 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, 全宇生技-KY (4148) achieved the “three margins increasing” benchmark, with a gross margin of 26.93%%, operating margin of 11.55%%, and net margin of 9.42%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4148's profit trajectory and future growth potential.
According to the past four quarterly reports, 全宇生技-KY (4148)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 1.02. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
全宇生技-KY (4148)'s Free Cash Flow (FCF) for the period is -54.71M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 76.85% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.